Dossier - 11/10/2023 The quantum revolution in the healthcare industry From ultra-fast quantum computers to highly sensitive sensors - quantum technologies could take medicine a giant step forward. Possible areas of application range from drug development and early cancer detection to reading brain waves to control prostheses or exoskeletons. The German state of Baden-Württemberg plays a key role in the development of sensors in particular.
Help with osteoarthritis of the knee - 27/09/2023 Individualised knee-joint cartilage: artificial tissue that fits Knee joints are subject to considerable stress throughout our lives. The natural shock absorber cartilage wears out over a lifetime, so many people develop knee osteoarthritis. Treatment is available in the form of artificial cartilage. This "off-the-shelf" tissue often does not grow well. Researchers are developing an individualised cartilage replacement made from biomaterial that is produced by 3D printing based on MRI images.
Project SMARTGAIT - 13/09/2023 Safe and cost-effective analysis of neurological gait disorders with AI Stroke, Parkinson's disease and multiple sclerosis often resulting in gait disorders in those affected. Gait analyses play a crucial role in the successful evaluation and therapy of such disorders. Current measurement methods are costly and time-consuming. The SMARTGAIT project is therefore developing an innovative AI-based system aimed at performing meaningful gait analyses with the help of simple smartphone video recordings.
Sustainability report - 31/08/2023 ReKlimaMed: how effective is the German healthcare sector when it comes to sustainability? Hospitals, care facilities and the healthcare industry, together with laboratories, private practices and pharmacies, ensure our medical care, but in so doing they produce enormous amounts of greenhouse gases and consume many resources. The ReKlimaMed report prepared by the viamedica foundation presents an inventory of current sustainable activities, and provides stakeholders with information and recommendations for action.
DNA nanotechnology - 25/08/2023 Artificial cytoskeleton made of DNA for synthetic cells The physicists Prof. Dr. Kerstin Göpfrich and Prof. Dr. Laura Na Liu want to understand life from the bottom up. They intend to do this by constructing an artificial cell. However, rather than natural protein building blocks, they are using 3D-DNA structures as construction material. The first step involved creating an artificial cell skeleton that dynamically assembles and disassembles like the biological model and can transport vesicles.
Project BlindZero - 03/08/2023 Hope for patients with eye diseases: human cornea from 3D printers Thousands of cornea transplants are performed every year. However, donors are rare and the procedure is not always without complications. Researchers at the University of Heidelberg are developing an innovative technique in the project BlindZero. It involves ‘printing’ human corneas directly onto patients’ eyes using 3D bioprinting. The reprogrammed genetically engineered cells used for this purpose are not expected to cause a rejection reaction.
NeuroQ project - 26/07/2023 Quantum sensors for exoskeletons: can quantum physics beat paralysis? Could people suddenly be able to move again decades after being paralysed? State-of-the-art quantum sensors integrated in exoskeletons could make this possible. Technology being developed as part of the BMBF-funded NeuroQ beacon project by researchers from organisations including the Fraunhofer IAF, the Charité in Berlin and the University of Stuttgart might achieve even more: besides facilitating movement, it could also help cure paralysis.
Tumour organoids facilitate drug discovery - 20/07/2023 Drug screening for children with cancer using patient-specific miniature tumours Standard drugs often don’t work in children and adolescents with recurrent cancer. Researchers from the Hopp Children's Tumour Centre (KITZ) and the German Cancer Research Center (DKFZ) in Heidelberg have been looking to open up new therapy options for those affected, and have cultivated individual miniature tumours from biopsy samples to test the effectiveness of a variety of drugs within a few weeks.
Expert interview - 05/07/2023 Every tenth of a degree matters when it comes to mitigating the consequences of global warming: sustainability measures in the laboratory The life sciences sector consumes huge quantities of energy and resources. This needs to change and we have to think differently. But how and where can sustainability measures be sensibly applied in the laboratory without compromising the quality of research results? Dr. Kerstin Hermuth-Kleinschmidt, owner of NIUB-Nachhaltigkeitsberatung, a company from Freiburg that focuses on sustainability in life sciences, tells BIOPRO how this can be done.
Expert interview - 28/06/2023 Money isn't all that is needed – knowledge and networking can also help start-ups move forward Dr. Rolf Neuhaus is one of the driving forces behind PALATINA Business Angels Rhein-Neckar e.V., a business angels association in the Rhine-Neckar metropolitan region. In an interview with BIOPRO, Neuhaus describes the association’s activities and explains where there is still catching up to be done in terms of start-up support in Baden-Württemberg.
Predicting the success of cancer treatment - 20/06/2023 Focusing on gut microbiome for CAR T-cell therapy Cancer immunotherapies use the body's own defences to fight tumour cells. An international consortium of researchers from Germany and the USA led by the DKFZ in Heidelberg has demonstrated that the effectiveness of CAR T-cell therapies greatly depends on the composition of the gut microbiome. The researchers have also developed a model for predicting the long-term response to the treatment.
Reduced immunosuppression possible in transplantations - 05/06/2023 Modified immune cells produce donor-specific tolerance Traditionally, transplant recipients have had to take immunosuppressive medication for life to prevent organ rejection. However, there are considerable side effects involved. Using modified immune cells (MICs), TolerogenixX GmbH from Heidelberg has now managed to generate donor-specific tolerance in recipients of living kidney transplants without suppressing the overall immune system.
